Cisplatin, immunotherapy, and chemoradiation in nasopharyngeal carcinoma: How far should one trial move the needle?
In patients with locoregionally advanced, Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma, the DIAMOND trial demonstrated that eliminating the concurrent cisplatin radiosensitizer while m
APA
Sun F, Colevas AD (2025). Cisplatin, immunotherapy, and chemoradiation in nasopharyngeal carcinoma: How far should one trial move the needle?. Med (New York, N.Y.), 6(11), 100917. https://doi.org/10.1016/j.medj.2025.100917
MLA
Sun F, et al.. "Cisplatin, immunotherapy, and chemoradiation in nasopharyngeal carcinoma: How far should one trial move the needle?." Med (New York, N.Y.), vol. 6, no. 11, 2025, pp. 100917.
PMID
41240897
Abstract
In patients with locoregionally advanced, Epstein-Barr virus (EBV)-associated nasopharyngeal carcinoma, the DIAMOND trial demonstrated that eliminating the concurrent cisplatin radiosensitizer while maintaining PD-1 inhibition throughout a treatment course anchored by gemcitabine-cisplatin induction resulted in non-inferior three-year failure-free survival and significantly lower all-grade vomiting. While such a strategy may be considered for cisplatin-ineligible patients, substitution of immunotherapy for concurrent cisplatin in all-comers remains premature.
MeSH Terms
Humans; Nasopharyngeal Carcinoma; Cisplatin; Nasopharyngeal Neoplasms; Chemoradiotherapy; Immunotherapy; Epstein-Barr Virus Infections; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Gemcitabine; Herpesvirus 4, Human
같은 제1저자의 인용 많은 논문 (5)
- Multicenter real-world data on immunotherapy for R/M HNSCC from China: comprehensive analysis of efficacy and survival differences across diverse clinical backgrounds, and identification of predictive peripheral blood biomarkers.
- Targeting CAMK1D-engineered nanoactivator suppresses cancer stem cell maintenance and immune evasion in enzalutamide-resistant prostate cancer.
- FOSL2 regulates PD-L1 and modulates hormone therapy response heterogeneity.
- Real-world efficacy of first-line immunochemotherapy combined with thoracic radiotherapy in elderly patients with extensive-stage small cell lung cancer: a single-center retrospective study.
- Association of endocrine immune-related adverse events with progression-free survival in advanced non-small cell lung cancer treated with PD-1/PD-L1 inhibitors with or without anlotinib.